Meeting
2015 Genitourinary Cancers Symposium
3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.
Authors
Chris Parker
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom
Chris Parker , Nicholas J. Vogelzang , A. Oliver Sartor , Robert E. Coleman , Fang Fang , Irene Skjorestad , Sten Nilsson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00699751
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 195)
DOI
10.1200/jco.2015.33.7_suppl.195
Abstract #
195
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
First Author: Steven E. Finkelstein
Poster
2013 ASCO Annual Meeting
Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial.
First Author: Chris Parker
Poster
2021 ASCO Annual Meeting
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2021 Genitourinary Cancers Symposium
Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB.
First Author: Hiroji Uemura